|Bid||18.31 x 800|
|Ask||18.44 x 1800|
|Day's Range||17.98 - 18.77|
|52 Week Range||11.65 - 36.65|
|Beta (3Y Monthly)||2.82|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 7, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||29.69|
STAINES-UPON-THAMES, United Kingdom, April 24, 2019 /PRNewswire/ -- Mallinckrodt plc (MNK), a leading global specialty pharmaceutical company, today celebrated the completion of its expanded operations and manufacturing facility for the investigational StrataGraft® regenerative skin tissue, in Madison, Wis. Stratatech, a Mallinckrodt company, recently completed patient enrollment in its ongoing pivotal Phase 3 clinical trial, which is evaluating the efficacy and safety of StrataGraft in the promotion of autologous skin regeneration of complex skin defects due to severe thermal burns that contain intact dermal elements (also known as deep partial-thickness burns). The safety and effectiveness of StrataGraft have not yet been established by the U.S. Food and Drug Administration (FDA).
This is high in the context of Mallinckrodt's business risks. Further, the company faces a number of headwinds over the next several years including the loss of patent exclusivity on Ofirmev in January 2021 and rising competitive pressures in Mallinckrodt's largest franchises. Absent significant progress in its pipeline, Moody's believes Mallinckrodt will face multiple years of earnings stagnation or declines.
STAINES-UPON-THAMES, United Kingdom, April 23, 2019 /PRNewswire/ -- Mallinckrodt plc (MNK), a leading global specialty pharmaceutical company, today confirmed it has completed enrollment in the company's Phase 4 clinical study assessing the efficacy and safety of Acthar® Gel in Systemic Lupus Erythematosus (lupus, SLE) patients with persistently active disease. This randomized, double-blind, placebo-controlled trial builds on data from a pilot study of Acthar Gel in patients with active SLE. The trial completed enrollment several months ahead of schedule in this underserved population, with a final count of 172 patients.
Some stocks are best avoided. It hits us in the gut when we see fellow investors suffer a loss. Imagine if you held Mallinckrodt plc (NYSE:MNK) for half a decade as the share price tanked 74%. On top of that, the sha...
STAINES-UPON-THAMES, United Kingdom, April 18, 2019 /PRNewswire/ -- Mallinckrodt plc (MNK), a leading global specialty pharmaceutical company, today announced top-line results from its company-sponsored, proof-of-concept study of nitric oxide gas (gNO) with ex-vivo lung perfusion compared to lung perfusion alone in human lung transplants. The study's primary objectives were to assess the effect of nitric oxide in perfused ex-vivo lungs using an experimental, proprietary grading system to evaluate improvements in lung function including oxygenation and transplantability, as well as the total ex-vivo perfusion time of the lungs through periodic assessments during Ex-Vivo Lung Perfusion (EVLP) as compared to standard of care alone.
Mallinckrodt (MNK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Dr. Reddy's (RDY) inks agreement to acquire the yet-to-be-marketed portfolio of 42 non-marketed Abbreviated New Drug Applications (ANDAs) in the United States.
Mallinckrodt (MNK) ends enrollment in the phase III study on StrataGraft, a regenerative skin tissue used in patients with thermal burns.
-- Retrospective analysis showed applying latest International Club of Ascites (ICA) diagnostic criteria would be estimated to result in earlier time to treatment at a lower SCr level and potentially improved ...
Zacks Value Trader Highlights: G-III Apparel, General Motors, Legg Mason, Mallinckrodt and United Natural Foods
Zacks.com featured expert Kevin Matras highlights: Mallinckrodt Public, Bayer Aktiengesellschaft, United Natural Foods, Tutor Perini and G-III Apparel
STAINES-UPON-THAMES, United Kingdom, April 12, 2019 /PRNewswire/ -- Mallinckrodt plc (MNK), a leading global specialty pharmaceutical company, today announced that Stratatech, a Mallinckrodt company, has completed patient enrollment in its ongoing pivotal Phase 3 clinical trial of StrataGraft®, an investigational regenerative skin tissue. The multicenter study is evaluating the efficacy and safety of StrataGraft in the promotion of autologous skin regeneration of complex skin defects due to severe thermal burns that contain intact dermal elements (also known as deep partial-thickness burns).
STAINES-UPON-THAMES, United Kingdom, April 11, 2019 /PRNewswire/ -- Mallinckrodt plc (MNK), a leading global specialty pharmaceutical company, today announced it has selected the first collaborative research endeavor with Washington University School of Medicine in St. Louis, a leader in medical research, teaching and patient care, under the multi-year partnership formed in 2018. Scientists from the company and the university are working jointly on this discovery program, aimed at identifying potential new drugs that will target chronic itch. The lack of understanding of chronic itch-specific mediators makes the translational research particularly difficult. Scientists in the Washington University laboratory found a receptor expressed in the spinal cord dorsal horn – a section of the spinal cord containing sensory neurons – and have shown that it functions as an itch-specific receptor.
Mallinckrodt (MNK) closed the most recent trading day at $23.58, moving -1.13% from the previous trading session.
STAINES-UPON-THAMES, United Kingdom, April 9, 2019 /PRNewswire/ -- Mallinckrodt plc (MNK), a leading global specialty pharmaceutical company, today announced data from a retrospective chart review that analyzed physician assessments of 91 U.S. patients diagnosed with uveitis who had been treated with Acthar® Gel (repository corticotropin injection) in the previous 12 months. In response to a survey question, physicians reported that 84 percent of patients who completed or were still in treatment with Acthar Gel had improvement in disease status overall, and 86 percent had improvements in vision. Uveitis is a leading cause of preventable blindness in adults.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
St. Louis stocks got off to a strong start in the first quarter, up 8.5 percent, but they trailed the broader stock market.